Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment

Author(s): Md. Asiful Islam, Fahmida Alam, Teguh Haryo Sasongko, Siew Hua Gan

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 28 , 2016

Become EABM
Become Reviewer
Call for Editor


Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by a persistently high titer of antiphospholipid antibodies (aPLs). In addition to pregnancy morbidity, arterial and/or venous thrombosis is another clinical feature of APS. Regardless of the type of APS, the thrombi formed by the induction of aPLs can lead to deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke and gangrene. Although the concept of APS was introduced approximately 32 years ago, its thrombogenic pathophysiology is still unclear. Therefore, patients are treated with anticoagulant and/or antiplatelet regimens just as in other thrombotic disorders even though the thrombotic pathophysiology is mainly aPLs-mediated. In this review, we provided an update of the cellular, auto-immune and genetic factors known to play important roles in the generation of thrombi. Current successful regimens are also outlined along with potential emerging treatment strategies that may lead to the optimum management of thrombotic APS patients.

Keywords: Antiphospholipid syndrome, antiphospholipid antibodies, thrombosis, pathophysiology, management.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 31 August, 2016
Page: [4451 - 4469]
Pages: 19
DOI: 10.2174/1381612822666160527160029
Price: $65

Article Metrics

PDF: 61
PRC: 1